Taiwan’s largest pharmaceutical manufacturer, Bora Pharmaceuticals, has announced the approval by its Board of Directors for the acquisition of generics manufacturer, Upsher-Smith, which is based in Minnesota, USA, for a total of $210 million.
According to a Jan. 16, 2024 press release, this acquisition—the inaugural one for Bora in the US—marks a pivotal expansion for the company into the US market. Additionally, the acquisition creates additional capacity for Bora’s global contract development and manufacturing organization (CDMO) business and also completes the company’s capabilities to serve its customers throughout the entire value chain.
